IDEXX LABORATORIES INC /DE Increase (Decrease) in Accounts Payable
IDEXX LABORATORIES INC /DE (IDXX) reported Increase (Decrease) in Accounts Payable of $4.48 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-04
- IDEXX LABORATORIES INC /DE increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$6.74M.
- IDEXX LABORATORIES INC /DE increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $11.22M.
- IDEXX LABORATORIES INC /DE increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$3.60M, a 162.66% decline year-over-year.
- IDEXX LABORATORIES INC /DE increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $7.14M.
- IDEXX LABORATORIES INC /DE increase (decrease) in accounts payable for fiscal 2025 was -$8.57M, a 206.02% decline from fiscal 2024.
- IDEXX LABORATORIES INC /DE increase (decrease) in accounts payable for fiscal 2024 was $8.09M.
- IDEXX LABORATORIES INC /DE increase (decrease) in accounts payable for fiscal 2023 was -$557.00K, a 116.07% decline from fiscal 2022.
- IDEXX LABORATORIES INC /DE increase (decrease) in accounts payable for fiscal 2022 was $3.47M.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$6.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $4.48M 10-Q · filed 2026-08-04 | $885.00K derived: sum of 3 quarters · filed 2026-08-04 | $8.02M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $11.22M 10-Q · filed 2026-05-05 | $7.62M derived: sum of 2 quarters · filed 2026-05-05 | $14.76M derived: sum of 3 quarters · filed 2026-05-05 | $10.77M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$3.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $3.54M derived: sum of 2 quarters · filed 2026-02-20 | -$450.00K derived: sum of 3 quarters · filed 2026-08-04 | -$8.57M 10-K · filed 2026-02-20 |
| 2025-09-30 | $7.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $3.15M derived: sum of 2 quarters · filed 2026-08-04 | -$4.98M 10-Q · filed 2025-11-03 | $762.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$3.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$12.11M 10-Q · filed 2026-08-04 | -$6.37M derived: sum of 3 quarters · filed 2026-08-04 | -$7.83M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$8.12M 10-Q · filed 2026-05-05 | -$2.38M derived: sum of 2 quarters · filed 2026-05-05 | -$3.84M derived: sum of 3 quarters · filed 2026-05-05 | $4.41M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $5.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $4.28M derived: sum of 2 quarters · filed 2026-02-20 | $12.54M derived: sum of 3 quarters · filed 2026-02-20 | $8.09M 10-K · filed 2026-02-20 |
| 2024-09-30 | -$1.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $6.80M derived: sum of 2 quarters · filed 2025-11-03 | $2.35M 10-Q · filed 2025-11-03 | $8.59M derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-06-30 | $8.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $3.80M 10-Q · filed 2025-08-04 | $10.04M derived: sum of 3 quarters · filed 2026-02-20 | $7.40M derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-03-31 | -$4.45M 10-Q · filed 2025-05-01 | $1.79M derived: sum of 2 quarters · filed 2026-02-20 | -$852.00K derived: sum of 3 quarters · filed 2026-02-20 | -$8.33M derived: sum of 4 quarters · filed 2026-02-20 |
| 2023-12-31 | $6.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $3.60M derived: sum of 2 quarters · filed 2026-02-20 | -$3.88M derived: sum of 3 quarters · filed 2026-02-20 | -$557.00K 10-K · filed 2026-02-20 |
| 2023-09-30 | -$2.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$10.13M derived: sum of 2 quarters · filed 2024-10-31 | -$6.80M 10-Q · filed 2024-10-31 | |
| 2023-06-30 | -$7.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$4.16M 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | $3.33M 10-Q · filed 2024-05-01 | |||
| 2022-12-31 | $3.47M 10-K · filed 2025-02-21 | |||
| 2010-09-30 | $1.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-22 | $6.11M 10-Q · filed 2010-10-22 | ||
| 2010-06-30 | $4.31M 10-Q · filed 2010-07-23 | |||
| 2009-09-30 | -$5.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-22 | -$6.87M 10-Q · filed 2010-10-22 | ||
| 2009-06-30 | -$1.68M 10-Q · filed 2010-07-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | United States | $6.510B | 26.31 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |